Oak Thistle LLC increased its holdings in Kenvue Inc. (NYSE:KVUE – Free Report) by 13.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,150 shares of the company’s stock after acquiring an additional 3,803 shares during the period. Oak Thistle LLC’s holdings in Kenvue were worth $665,000 at the end of the most recent reporting period.
A number of other hedge funds have also made changes to their positions in the stock. Riverview Trust Co purchased a new stake in shares of Kenvue during the third quarter worth $30,000. Ashton Thomas Securities LLC acquired a new stake in Kenvue in the 3rd quarter worth approximately $35,000. Fortitude Family Office LLC lifted its stake in shares of Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after buying an additional 777 shares during the last quarter. Versant Capital Management Inc boosted its holdings in Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after acquiring an additional 1,441 shares during the period. Finally, Deseret Mutual Benefit Administrators boosted its stake in Kenvue by 49.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock valued at $45,000 after purchasing an additional 651 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.
Kenvue Stock Performance
NYSE KVUE opened at $20.83 on Thursday. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The firm has a market capitalization of $39.94 billion, a price-to-earnings ratio of 37.87, a P/E/G ratio of 2.02 and a beta of 1.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm’s 50 day simple moving average is $22.50 and its 200 day simple moving average is $21.64.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on KVUE. Royal Bank of Canada upgraded shares of Kenvue from a “hold” rating to a “moderate buy” rating in a research note on Monday, December 9th. Barclays upgraded shares of Kenvue to a “hold” rating in a research note on Thursday, December 12th. Citigroup reduced their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Finally, Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $23.18.
Read Our Latest Analysis on KVUE
Kenvue Profile
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Stories
- Five stocks we like better than Kenvue
- How is Compound Interest Calculated?
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- 3 Grocery Stocks That Are Proving They Are Still Essential
- How Do Stock Buybacks Affect Shareholders?
- What is a Death Cross in Stocks?
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.